Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Skye Bioscience, Inc. Common Stock
SKYECurrent price
6 USD
0 USD (0.00%)
Last closed
6 USD
Company
skyebioscience.com
ISIN
US83086J1016
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
192 648 208 USD
Yield for 12 month
+180.37 %
1Y
3Y
5Y
10Y
15Y
SKYE
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapeutic drugs that modulate the endocannabinoid system. The company's lead clinical program's product candidate is nimacimab, a peripherally-restricted negative allosteric modulating antibody specific for the human cannabinoid receptor 1 (CB1) receptor, administered as a subcutaneous injectable that is Phase II clinical trials for the treatment of metabolic disorders, including obesity. It is also developing SBI-100 Ophthalmic Emulsion,a CB1 agonist that is Phase II clinical trials for the treatment of glaucoma and ocular hypertension. It has licensing agreement with Tautomer Bioscience, (Pty) Limited to develop and commercialize SBI-100; and collaborative research agreement with VivaCell Biotechnology Espana, S.L.U for the research and development of SBI-200 and the preclinical development services for novel derivatives. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. Address: 11250 El Camino Real, San Diego, CA, United States, 92130
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
18.25 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-124 251 USD
Last Year
-114 998 USD
Current Quarter
–
Last Quarter
–
Key Figures SKYE
1 year
3 years
5 years
10 years
EBITDA
-22 021 516 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-30.92 %
PEG Ratio
–
Return On Equity TTM
-130.08 %
Wall Street Target Price
18.25 USD
Revenue TTM
–
Book Value
2.59 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-3.6 USD
Diluted Eps TTM
-3.6 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics SKYE
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SKYE
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:250
Payout Ratio
–
Last Split Date
08.09.2023
Dividend Date
–
Stock Valuation SKYE
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-2.5612
Price Book MRQ
2.6543
Financials SKYE
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators SKYE
For 52 weeks
1.44 USD
19.41 USD
50 Day MA
5.87 USD
Shares Short Prior Month
1 013 708
200 Day MA
7.88 USD
Short Ratio
5.53
Shares Short
1 045 378
Short Percent
5.19 %
BeatStart